Mostrando 10 resultados de: 12
Filtros aplicados
Subtipo de publicación
Other(12)
Área temáticas
Enfermedades(10)
Farmacología y terapéutica(6)
Ginecología, obstetricia, pediatría, geriatría(3)
Medicina y salud(3)
Cirugía y especialidades médicas afines(1)
Origen
google(12)
Clinical management and resolution of stomatitis in BOLERO-2.
OtherAbstract: 558 Background: In BOLERO-2, adding everolimus (EVE) to exemestane (EXE) more than doubled progressiPalabras claves:Autores:Alejandra PérezFuentes:googleCorrelation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
OtherAbstract: LBA509 Background: Everolimus (EVE) plus exemestane (EXE) more than doubled progression-free survivaPalabras claves:Autores:Alejandra PérezFuentes:googleCorrelative analysis of genetic alterations and everolimus benefit in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer …
OtherAbstract: Purpose To explore the genetic landscape of tumors from patients enrolled on the BOLERO-2 trial to iPalabras claves:Autores:Alejandra PérezFuentes:googleAcupuncture for the management of hot flashes in women with early stage breast cancer treated with tamoxifen or an aromatase inhibitor: A pilot study of efficacy, safety and …
OtherAbstract: 703 Background: With the increasing use and duration of endocrine therapies in the treatment of adjuPalabras claves:Autores:Alejandra PérezFuentes:googleEverolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or …
OtherAbstract: e11058 Background: The PI3K/Akt/mTOR pathway, a key regulator of cellular proliferation, cellular mePalabras claves:Autores:Alejandra PérezFuentes:googleIncidence, management, and resolution of stomatitis and noninfectious pneumonitis in BOLERO-2.
OtherAbstract: 159 Background: Although the mTOR inhibitor everolimus (EVE) was generally well tolerated in combinaPalabras claves:Autores:Alejandra PérezFuentes:googleImpact of obesity on survival and recurrence of high grade serous carcinoma of the ovary.
OtherAbstract: e17081 Background: Obesity is a public health problem in most developed countries, with growing inciPalabras claves:Autores:Alejandra PérezFuentes:googleImpact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients …
OtherAbstract: 1048 Background: A preferred NAC regimen for HER2-negative BC is DDAC for 4 cycles followed by 12 wePalabras claves:Autores:Alejandra PérezFuentes:googleUpdated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer.
OtherAbstract: 1046 Background: Although concomitant trastuzumab and paclitaxel is an established treatment for metPalabras claves:Autores:Alejandra PérezFuentes:googleUpdated results of a multicenter Phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC)
OtherAbstract: 10685 Background: Neoadjuvant chemotherapy for the treatment of LABC has become the standard of carePalabras claves:Autores:Alejandra PérezFuentes:google